Stryker (SYK) Earns Daily News Sentiment Score of 0.20
News coverage about Stryker (NYSE:SYK) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stryker earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the medical technology company an impact score of 46.5915050051327 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Stryker Corporation (NYSE:SYK) – Glistening Stock’s Review – Nasdaq Journal (press release) (nasdaqjournal.com)
- Active Stock Evaluation – Stryker Corporation, (NYSE: SYK) – Stock Watch (stocksnewstimes.com)
- Noteworthy Thursday Option Activity: LAD, AEIS, SYK (nasdaq.com)
- Stryker’s Inorganic Growth Strategy Continues to Boost Growth (finance.yahoo.com)
- Tracking Technical Indicators on Stryker Corporation (SYK) – Wall Street Morning (wallstreetmorning.com)
A number of research firms have commented on SYK. BMO Capital Markets raised Stryker to a “market perform” rating and set a $163.00 price target on the stock in a report on Tuesday, December 12th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a report on Thursday, December 7th. ValuEngine cut Stryker from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating in a report on Friday, November 24th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $161.00 target price on shares of Stryker in a report on Friday, November 17th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $154.20.
Shares of Stryker (SYK) traded up $0.04 during mid-day trading on Friday, hitting $154.14. The stock had a trading volume of 581,270 shares, compared to its average volume of 1,225,545. Stryker has a 1 year low of $116.50 and a 1 year high of $160.62. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $57,670.02, a PE ratio of 32.94, a price-to-earnings-growth ratio of 2.43 and a beta of 0.78.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The firm’s revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the business posted $1.39 earnings per share. research analysts forecast that Stryker will post 6.47 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be given a $0.47 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.88 annualized dividend and a yield of 1.22%. This is a positive change from Stryker’s previous quarterly dividend of $0.43. Stryker’s dividend payout ratio (DPR) is currently 36.32%.
In related news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the transaction, the insider now owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 7.40% of the company’s stock.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with Analyst Ratings Network's FREE daily email newsletter.